FY2025 Earnings Estimate for CRBU Issued By Leerink Partnrs

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Stock analysts at Leerink Partnrs reduced their FY2025 EPS estimates for Caribou Biosciences in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($1.77) per share for the year, down from their prior estimate of ($1.64). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. Leerink Partnrs also issued estimates for Caribou Biosciences’ FY2026 earnings at ($1.84) EPS, FY2027 earnings at ($1.83) EPS, FY2028 earnings at ($0.54) EPS and FY2029 earnings at $0.28 EPS.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The company had revenue of $2.02 million for the quarter, compared to the consensus estimate of $3.37 million.

CRBU has been the topic of several other research reports. Bank of America decreased their price objective on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a research note on Friday, November 15th. Finally, Citigroup dropped their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 26th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $10.33.

Caribou Biosciences Stock Down 0.7 %

Shares of CRBU opened at $1.51 on Friday. The stock’s 50-day moving average price is $1.83 and its 200 day moving average price is $2.00. The firm has a market capitalization of $136.73 million, a price-to-earnings ratio of -0.92 and a beta of 2.34. Caribou Biosciences has a 12-month low of $1.47 and a 12-month high of $8.33.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC acquired a new position in Caribou Biosciences in the second quarter valued at about $2,432,000. Dimensional Fund Advisors LP boosted its holdings in shares of Caribou Biosciences by 25.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock worth $4,302,000 after acquiring an additional 536,162 shares in the last quarter. PFM Health Sciences LP grew its position in Caribou Biosciences by 5.5% during the 3rd quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock worth $8,441,000 after acquiring an additional 223,299 shares during the last quarter. XTX Topco Ltd acquired a new stake in Caribou Biosciences during the 2nd quarter valued at $341,000. Finally, Geode Capital Management LLC raised its position in Caribou Biosciences by 6.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after purchasing an additional 124,782 shares during the last quarter. 77.51% of the stock is owned by institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.